GOODWILL, IPR&D AND OTHER INTANGIBLE ASSETS, NET (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of carrying value of the entity's IPR&D assets

The carrying value of our IPR&D assets consisted of the following at:

	September 30, 2014		December 31, 2013
	(in thousands)
Development and potential commercialization of:
SIVEXTRO	$	—	$	659,000
Bevenopran	43,400		43,400
ZERBAXA for HABP and VABP	174,000		174,000
ZERBAXA for cUTI and cIAI	20,000		20,000
Total IPR&D	$	237,400	$	896,400

Schedule of other intangible assets, net

Other intangible assets, net consisted of the following at: 

		September 30, 2014			December 31, 2013
		(in thousands)
Patents		$	2,627		$	2,627
Acquired technology rights		1,451,800			788,800
Other intangible assets, gross		1,454,427			791,427
Less:	accumulated amortization — patents	(2,539		)	(2,493		)
	accumulated amortization — acquired technology rights	(129,506		)	(67,868		)
Other intangible assets, net		$	1,322,382		$	721,066

Schedule of estimated aggregate amortization of intangible assets

The estimated aggregate amortization of intangible assets as of September 30, 2014, for each of the five succeeding years and thereafter is as follows: 

	(in thousands)
Remainder of 2014	$	28,002
2015	112,004
2016	110,724
2017	109,484
2018	109,484
2019 and thereafter	852,684
Total	$	1,322,382